DPP4-Inhibitors and Bone Metabolism in Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 132 participants.
Also called NCT06770894
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 132 participants
- Sponsor
- Azienda Policlinico Umberto I
- Registry
-
NCT06770894 -
2018-000859-40
-
- Other papers using this trial's data
- Effect of sitagliptin vs. placebo on bone mineralization in women with type 2 diabetes: the SLowDOWN (SitagLiptin in Diabetes for Osteoporosis in WomeN) randomized clinical trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Italy
- Registry status
- Completed
Technical summary
Registry record NCT06770894. Randomized; triple masking; primary purpose treatment. Start 2019-09-24 (actual); primary completion 2023-10-10 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- DPP4-Inhibitors and Bone Metabolism in Diabetes
- Acronym
- SlowDOWN
- Condition
- Osteoporosis
- Condition
- Bone Loss, Postmenopausal
- Condition
- Diabetes Mellitus Type 2
- Intervention (Drug)
- Sitagliptin 100 mg
- Intervention (Drug)
- Placebo Tablets
- Lead sponsor
- Azienda Policlinico Umberto I
- Collaborator
- Agenzia Italiana del Farmaco
Record details
- Record id
cardio:ct-nct06770894- Content hash
ef159945db8d7a07a492252aa7f0d2e0a597928c560524f357079f3cdaaec74d